Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/SB-334,867> ?p ?o }
Showing triples 1 to 74 of
74
with 100 triples per page.
- SB-334,867 abstract "SB-334867 is an orexin antagonist. It was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX1, with around 50x selectivity for OX1 over OX2 receptors. It has been shown to produce sedative and anorectic effects in animals, and has been useful in characterising the orexinergic regulation of brain systems involved with appetite and sleep, as well as other physiological processes. Orexin antagonists have multiple potential clinical applications including the treatment of drug addiction, insomnia, obesity and diabetes.".
- SB-334,867 casNumber "249889-64-3".
- SB-334,867 iupacName "1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl urea".
- SB-334,867 pubchem "6604926".
- SB-334,867 thumbnail SB-334,867.svg?width=300.
- SB-334,867 wikiPageID "22230687".
- SB-334,867 wikiPageLength "10610".
- SB-334,867 wikiPageOutDegree "11".
- SB-334,867 wikiPageRevisionID "679038011".
- SB-334,867 wikiPageWikiLink Anorectic.
- SB-334,867 wikiPageWikiLink Category:Benzoxazoles.
- SB-334,867 wikiPageWikiLink Category:Naphthyridines.
- SB-334,867 wikiPageWikiLink Category:Orexin_antagonists.
- SB-334,867 wikiPageWikiLink Category:Sedatives.
- SB-334,867 wikiPageWikiLink Category:Ureas.
- SB-334,867 wikiPageWikiLink Hypocretin_(orexin)_receptor_1.
- SB-334,867 wikiPageWikiLink Hypocretin_(orexin)_receptor_2.
- SB-334,867 wikiPageWikiLink Orexin_antagonist.
- SB-334,867 wikiPageWikiLink Orexin_receptor.
- SB-334,867 wikiPageWikiLink Sedative.
- SB-334,867 wikiPageWikiLinkText "SB-334,867".
- SB-334,867 c "17".
- SB-334,867 casNumber "249889".
- SB-334,867 chembl "291536".
- SB-334,867 chemspiderid "5037182".
- SB-334,867 h "13".
- SB-334,867 inchi "1".
- SB-334,867 inchikey "AKMNUCBQGHFICM-UHFFFAOYAZ".
- SB-334,867 iupacName "1".
- SB-334,867 iupharLigand "1703".
- SB-334,867 molecularWeight "319.317".
- SB-334,867 n "5".
- SB-334,867 o "2".
- SB-334,867 pubchem "6604926".
- SB-334,867 smiles "O=CNc3ccc4ncC".
- SB-334,867 stdinchi "1".
- SB-334,867 stdinchikey "AKMNUCBQGHFICM-UHFFFAOYSA-N".
- SB-334,867 verifiedfields "changed".
- SB-334,867 verifiedrevid "464385140".
- SB-334,867 wikiPageUsesTemplate Template:Cascite.
- SB-334,867 wikiPageUsesTemplate Template:Chemspidercite.
- SB-334,867 wikiPageUsesTemplate Template:Drugbox.
- SB-334,867 wikiPageUsesTemplate Template:Ebicite.
- SB-334,867 wikiPageUsesTemplate Template:Hypnotics_and_sedatives.
- SB-334,867 wikiPageUsesTemplate Template:Neuropeptide_agonists_and_antagonists.
- SB-334,867 wikiPageUsesTemplate Template:Reflist.
- SB-334,867 wikiPageUsesTemplate Template:Sedative-stub.
- SB-334,867 wikiPageUsesTemplate Template:Stdinchicite.
- SB-334,867 subject Category:Benzoxazoles.
- SB-334,867 subject Category:Naphthyridines.
- SB-334,867 subject Category:Orexin_antagonists.
- SB-334,867 subject Category:Sedatives.
- SB-334,867 subject Category:Ureas.
- SB-334,867 hypernym Antagonist.
- SB-334,867 type ChemicalSubstance.
- SB-334,867 type Drug.
- SB-334,867 type Agonist.
- SB-334,867 type Amide.
- SB-334,867 type Antagonist.
- SB-334,867 type Drug.
- SB-334,867 type Heterocycle.
- SB-334,867 type ChemicalObject.
- SB-334,867 type Thing.
- SB-334,867 type Q8386.
- SB-334,867 comment "SB-334867 is an orexin antagonist. It was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX1, with around 50x selectivity for OX1 over OX2 receptors. It has been shown to produce sedative and anorectic effects in animals, and has been useful in characterising the orexinergic regulation of brain systems involved with appetite and sleep, as well as other physiological processes.".
- SB-334,867 label "SB-334,867".
- SB-334,867 sameAs Q7388911.
- SB-334,867 sameAs m.05q6jtj.
- SB-334,867 sameAs SB-334,867.
- SB-334,867 sameAs SB-334,867.
- SB-334,867 sameAs Q7388911.
- SB-334,867 wasDerivedFrom SB-334,867?oldid=679038011.
- SB-334,867 depiction SB-334,867.svg.
- SB-334,867 isPrimaryTopicOf SB-334,867.